Skip navigation

Browse by Material Type

Browse by Material Type

Up a level
Export as [feed] RSS
Group by: Creators | Uncontrolled Keywords | No Grouping
Number of items: 84.

3D printing

The University Of Greenwich (2017) STENT WO 2016116748 A1. WO 2016116748 A1.

aim-and-trigger devices

Keates et al. (2008) System and method for correcting positioning and triggering errors for aim-and-trigger devices. US20080266252 A1.

anticancer

University of Vermont (2017) Cymanquine compounds and derivatives thereof and uses thereof. .

antisense oligonucleotide

Richardson, Dyer, Mitchell (2014) WO 2014203008 A1 Antisense oligonucleotide compositions. WO2014203008 A1.

ASO

Richardson, Dyer, Mitchell (2014) WO 2014203008 A1 Antisense oligonucleotide compositions. WO2014203008 A1.

cancer

University of Vermont (2017) Cymanquine compounds and derivatives thereof and uses thereof. .

central nervous system

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. JP2011144195.

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

central nervous system diseases

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

coating

University of Greenwich (2013) Method of coating microneedle devices. WO 2013/038137.

Continuous flow

Professor John Mitchell (2016) US20160024229A1 Cyclodextrin. US20160024229 A1.

correcting positioning

Keates et al. (2008) System and method for correcting positioning and triggering errors for aim-and-trigger devices. US20080266252 A1.

Cyclic Triazo Sodium channel blockers

University of Greenwich (2017) HK1170726 (A1)2017-06-02 Cyclic triazo sodium channel blockers. HK1179726 (A1).

Cyclodextrin

John Mitchell (US 14/333,417) (2015) WO2015008066A1: Cyclodextrin US 20150025023 A1. .

Professor John Mitchell (2016) US20160024229A1 Cyclodextrin. US20160024229 A1.

cymanquine

University of Vermont (2017) Cymanquine compounds and derivatives thereof and uses thereof. .

cytokines

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

University of Greenwich (2016) Triazine derivatives as interferon gamma inhibitors. WO 2016/109978 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

cytosolic delivery

Richardson, Dyer, Mitchell (2014) WO 2014203008 A1 Antisense oligonucleotide compositions. WO2014203008 A1.

drug

University of Vermont (2017) Cymanquine compounds and derivatives thereof and uses thereof. .

errors triggering

Keates et al. (2008) System and method for correcting positioning and triggering errors for aim-and-trigger devices. US20080266252 A1.

Interferon gamma

University of Greenwich (2016) Triazine derivatives as interferon gamma inhibitors. WO 2016/109978 A1.

Interferon gamma inhibitors

University of Greenwich (2018) Triazine derivatives as interferon gamma inhibitors. EP 3307273 (A1).

jet-dispensing

University of Greenwich (2013) Method of coating microneedle devices. WO 2013/038137.

lamotrigine

BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.

medical use

University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.

Microneedles

University of Greenwich (2013) Method of coating microneedle devices. WO 2013/038137.

motion capture apparatus

Birmingham City University, Perry Barr, Birmingham, West Midlands B42 2SU (2010) MotivePro: a motion capture apparatus. WO/2010/084348.

multiple sclerosis

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. JP2011144195.

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

University of Greenwich, UK (2015) AU2014280981: Cyclic Triazo and Diazo channel blockers. .

University of Greenwich (2015) Medical uses of triazines. .

Michael Leach (2014) US2014243343 (A1)Cyclic triazo sodium channel blockers. .

University of Greenwich, UK (2015) US9000155: Cyclic triazo sodium channel blockers. .

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.

BTG International Limited (2008) Treatment of neurodegenerative conditions. GB2442161/B.

neurodegeneration

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. JP2011144195.

University of Greenwich, London UK (2014) HK1129206 (A1): New medical use of triazine derivatives. .

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

Neurodegenerative disease

University of Greenwich (2015) Medical uses of triazines. .

neurodegenerative diseases

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

BTG International Limited (2008) Treatment of neurodegenerative conditions. GB2442161/B.

Neurodegenerative disorders

University of Greenwich, UK (2015) US9000155: Cyclic triazo sodium channel blockers. .

Neurological disorders

Michael Leach (2014) US2014243343 (A1)Cyclic triazo sodium channel blockers. .

Neuroprotection

University of Greenwich (2016) Cyclic triazo and diazo sodium channel blockers US divisional. US2016/0311784A1.

University of Greenwich, London UK (2014) ES24629727 (T3): New medical use of triazines. .

University of Greenwich, UK (2012) KR20120048593 Cyclic triazo sodium channel blockers. KR20120048593 (A).

Neuroprotection Sodium channels Multiple sclerosis

University of Greenwich, London, UK (2014) US2014155403 Cyclic triazo and diazo sodium channel blockers. .

Neuroprotective

University of Greenwich, UK (2015) AU2014280981: Cyclic Triazo and Diazo channel blockers. .

organometallic

University of Vermont (2017) Cymanquine compounds and derivatives thereof and uses thereof. .

phospholipids

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

polyunsaturated fatty acids

BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

BTG International Limited (2004) Use of triglyceride oils containing gamma-linolenic residues and linoleic acid residues for the treatment of neurodegenerative disease. WO2004/100943 A1.

sodium channel blockers

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

University of Greenwich (2016) Cyclic triazo and diazo sodium channel blockers US divisional. US2016/0311784A1.

University of Greenwich, London UK (2014) ES24629727 (T3): New medical use of triazines. .

University of Greenwich, London UK (2014) HK1129206 (A1): New medical use of triazine derivatives. .

University of Greenwich, UK (2012) KR20120048593 Cyclic triazo sodium channel blockers. KR20120048593 (A).

Michael Leach (2014) US2014243343 (A1)Cyclic triazo sodium channel blockers. .

University of Greenwich, Old Royal Naval College Park Row, Greenwich London SE10 9LS (2009) Cyclic triazo and diazo sodium channel blockers. WO/2009/090431.

Stent

The University Of Greenwich (2017) STENT WO 2016116748 A1. WO 2016116748 A1.

structured phospholipids

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

Sulphoalkyl ether-β-cyclodextrin

Professor John Mitchell (2016) US20160024229A1 Cyclodextrin. US20160024229 A1.

treatment of multiple sclerosis

BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

BTG International Limited (2004) Use of triglyceride oils containing gamma-linolenic residues and linoleic acid residues for the treatment of neurodegenerative disease. WO2004/100943 A1.

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

BTG International Limited (2005) Treatment of neurodegenerative conditions. WO2005/018632/A1.

triazine derivatives

University of Greenwich (2018) Triazine derivatives as interferon gamma inhibitors. EP 3307273 (A1).

triazines

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

University of Greenwich, London UK (2014) HK1129206 (A1): New medical use of triazine derivatives. .

University of Greenwich (2016) Triazine derivatives as interferon gamma inhibitors. WO 2016/109978 A1.

University of Greenwich, UK (2015) US9000155: Cyclic triazo sodium channel blockers. .

University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.

University of Greenwich, Old Royal Naval College Park Row, Greenwich London SE10 9LS (2009) Cyclic triazo and diazo sodium channel blockers. WO/2009/090431.

triglycerides

BTG International Limited (2008) Treatment of neurodegenerative conditions. GB2442161/B.

use patent

BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.

uveitis

University of Greenwich (2015) Medical uses of triazines. .

Uveitis and other diseases

University of Greenwich, UK (2015) AU2014280981: Cyclic Triazo and Diazo channel blockers. .

This list was generated on Wed Jun 20 11:35:02 2018 BST.